Transkaryotic Therapies (NASDAQ:TKTX)
Historical Stock Chart
From Jun 2019 to Jun 2024
TKT to Report First Quarter 2005 Financial Results on May 5, 2005
CAMBRIDGE, Mass., April 27 /PRNewswire-FirstCall/ -- Transkaryotic Therapies,
Inc. (NASDAQ:TKTX) will announce its first quarter 2005 financial results on
May 5, 2005 before the open of U.S. financial markets. In connection with this
announcement, TKT will host a conference call and live audio webcast on May 5,
2005 at 10:00 a.m. Eastern Time to discuss its first quarter 2005 financial
results, the company's business activities, and financial outlook.
Participants may access the call by dialing (719) 457-2642. This call will also
be broadcast live over the Internet at http://www.tktx.com/ under the Investor
Information section. Please dial in 5 to 10 minutes prior to the scheduled
conference call time or log on to the website at least 15 minutes prior to the
call in order to register, download, and install any necessary software.
A replay of the conference call and webcast will be available once a transcript
has been filed with the Securities and Exchange Commission. Participants may
access this replay by dialing (719) 457-0820 and using the access code 2495707.
In addition, a replay of the webcast will be archived on the TKT website under
Events in the Investor Information section.
About TKT
Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused
on researching, developing and commercializing treatments for rare diseases
caused by protein deficiencies. Within this focus, the company markets
Replagal(TM), an enzyme replacement therapy for Fabry disease, and is
developing treatments for Hunter syndrome and Gaucher disease. In addition to
its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene-
Activated(R) erythropoietin product for anemia related to kidney disease, in
the European Union. TKT was founded in 1988 and is headquartered in Cambridge,
Massachusetts, with additional operations in Europe, Canada and South America.
Additional information about TKT is available on the company's website at
http://www.tktx.com/.
Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of
Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Sanofi-Aventis SA.
For More Information Contact:
Daniella M. Lutz
Manager, Corporate Communications
(617) 349-0205
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
http://photoarchive.ap.org/
DATASOURCE: Transkaryotic Therapies, Inc.
CONTACT: Daniella M. Lutz, Manager, Corporate Communications of TKT,
+1-617-349-0205
Web site: http://www.tktx.com/
Company News On-Call: http://www.prnewswire.com/comp/120657.html